An FDA advisory committee has voted 14-1 in favor of expanding the indication for the pneumococcal 13-valent conjugate vaccine (Prevnar 13) to include use in adults 50 and older.
Currently the vaccine is approved only for use in children.
The FDA's Vaccines and Related Biologics Advisory Committee voted for accelerated approval, reserved for biologics or drugs that are intended to treat serious or life-threatening illnesses and that provide a meaningful benefit over existing treatments.
Read the full story at: http://www.medpagetoday.com/InfectiousDisease/Vaccines/29755
Source: MedPage Today
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More